Gene therapy in cystic fibrosis

Michelle Prickett, Manu Jain*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene and is the most common life-shortening genetic defect in Caucasians. Life expectancy in CF has improved substantially over the last 75 years because of treatments aimed at end-organ complications. Since the CFTR gene was discovered in 1989 more than 1900 mutations have been reported to cause CF and significant effort has been put forth into gene therapy to find a mutation independent "cure" for CF. Gene-based approaches have not yet led to a viable therapy but have provided insights into hurdles that limit the efficacy of gene therapy. This review will address the nomenclature of CFTR mutations, attempts at viral and nonviral gene therapy, and recent advances in mutation-specific molecules.

Original languageEnglish (US)
Pages (from-to)255-264
Number of pages10
JournalTranslational Research
Issue number4
StatePublished - Apr 2013

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Biochemistry, medical
  • Physiology (medical)


Dive into the research topics of 'Gene therapy in cystic fibrosis'. Together they form a unique fingerprint.

Cite this